中国生物制药(01177)：库莫西利胶囊联合氟维司群注射液治疗内分泌经治的HR+/HER2-晚期乳腺癌III期研究数据在2024 CSCO公布

智通财经09-27

智通财经APP讯，中国生物制药(01177)发布公告，集团研发的1类创新药库莫西利胶囊已在2024年全国临床肿瘤学大会(2024 CSCO)以口头报告的形式公布了III期临床(TQB3616-III-01)最新研究成果，用于联合氟维司群注射液治疗内分泌经治的激素受体阳性╱人表皮生长因子受体2阴性(HR+/HER2-)晚期乳腺癌：中位无进展生存期(PFS)为16.62个月，客观缓解率(ORR)为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2470774519?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-27 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470774519","market":"us","top_or_hot":-1,"title":"中国生物制药(01177)：库莫西利胶囊联合氟维司群注射液治疗内分泌经治的HR+/HER2-晚期乳腺癌III期研究数据在2024 CSCO公布","media":"智通财经","content":"<div>\n<p>智通财经APP讯，中国生物制药(01177)发布公告，集团研发的1类创新药库莫西利胶囊已在2024年全国临床肿瘤学大会(2024 CSCO)以口头报告的形式公布了III期临床(TQB3616-III-01)最新研究成果，用于联合氟维司群注射液治疗内分泌经治的激素受体阳性╱人表皮生长因子受体2阴性(HR+/HER2-)晚期乳腺癌：中位无进展生存期(PFS)为16.62个月，客观缓解率(ORR)为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1188176.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国生物制药(01177)：库莫西利胶囊联合氟维司群注射液治疗内分泌经治的HR+/HER2-晚期乳腺癌III期研究数据在2024 CSCO公布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国生物制药(01177)：库莫西利胶囊联合氟维司群注射液治疗内分泌经治的HR+/HER2-晚期乳腺癌III期研究数据在2024 CSCO公布\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-27 17:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1188176.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，中国生物制药(01177)发布公告，集团研发的1类创新药库莫西利胶囊已在2024年全国临床肿瘤学大会(2024 CSCO)以口头报告的形式公布了III期临床(TQB3616-III-01)最新研究成果，用于联合氟维司群注射液治疗内分泌经治的激素受体阳性╱人表皮生长因子受体2阴性(HR+/HER2-)晚期乳腺癌：中位无进展生存期(PFS)为16.62个月，客观缓解率(ORR)为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1188176.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4525","symbol_name":"远程办公概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1188176.html","article_id":"2470774519","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470774519","pubTimestamp":1727428246,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，中国生物制药 发布公告，集团研发的1类创新药库莫西利胶囊已在2024年全国临床肿瘤学大会以口头报告的形式公布了III期临床最新研究成果，用于联合氟维司群注射液治疗内分泌经治的激素受体阳性╱人表皮生长因子受体2阴性晚期乳腺癌：中位无进展生存期为16.62个月，客观缓解率为40.21%，总生存期呈获益趋势。TQB3616-III-01是全球首个口服CDK2/4/6抑制剂联合内分泌治疗用于HR+/HER2-晚期乳腺癌取得阳性结果的III期试验。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4525":"远程办公概念","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","SG9999002232.USD":"Allianz Global High Payout USD","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","SG9999001424.SGD":"United E-Commerce Fund SGD","LU0731783394.SGD":"Fidelity Global Dividend A-MINCOME(G)-SGD","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","III":"信息服务","BK4527":"明星科技股","BK4020":"通信设备","BK4588":"碎股","LU1599440770.SGD":"FIDELITY GLOBAL DIVIDEND \"A\" (SGDHDG) INC","BK4134":"信息科技咨询与其它服务","01177":"中国生物制药","LU1046421795.USD":"富达环球科技A-ACC","LU2286300806.USD":"Allianz Cyber Security AT Acc USD","BK1521":"挪威政府全球养老基金持仓","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK1191":"制药","BK4581":"高盛持仓","BK4560":"网络安全概念","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","HR":"医疗保健房地产信托","LU1235294995.USD":"FIDELITY GLOBAL TECHNOLOGY \"A\" (USDHDG) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4203":"医疗保健房地产投资信托","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","CSCO":"思科","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","BK4225":"医疗保健房地产信托","SG9999002224.SGD":"Allianz Global High Payout SGD","BK1589":"北水核心资产","BK4585":"ETF&股票定投概念","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC"},"translate_title":"China Biopharmaceuticals (01177): Data from the phase III study of cumociclib capsules combined with fulvestrant injection in the treatment of endocrine-treated HR+/HER2-advanced breast cancer announced at 2024 CSCO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"01177":1,"HR":1,"CSCO":1},"content_text":"智通财经APP讯，中国生物制药(01177)发布公告，集团研发的1类创新药库莫西利胶囊已在2024年全国临床肿瘤学大会(2024 CSCO)以口头报告的形式公布了III期临床(TQB3616-III-01)最新研究成果，用于联合氟维司群注射液治疗内分泌经治的激素受体阳性╱人表皮生长因子受体2阴性(HR+/HER2-)晚期乳腺癌：中位无进展生存期(PFS)为16.62个月，客观缓解率(ORR)为40.21%，总生存期(OS)呈获益趋势。TQB3616-III-01是全球首个口服CDK2/4/6抑制剂联合内分泌治疗用于HR+/HER2-晚期乳腺癌取得阳性结果的III期试验。这是一项随机、双盲、平行对照、多中心临床研究，旨在评估库莫西利联合氟维司群(实验组)对比安慰剂联合氟维司群(对照组)在内分泌经治的HR+/HER2-晚期乳腺癌患者中的有效性和安全性。研究结果显示，库莫西利联合氟维司群组对比安慰剂联合氟维司群组的中位PFS为16.62个月vs. 7.46 个月。与对照组相比，库莫西利联合治疗的中位PFS延长9.16个月，疾病进展╱死亡风险降低64% (HR=0.36, P<0.0001)。主要研究结果中位PFS、风险比(HR)和PFS绝对获益程度均高于现有标准治疗的数据。集团在2024 CSCO公布了20余项最新研究成果，全面展示了集团在多个肿瘤治疗领域取得的突破性进展。未来，集团将继续聚焦创新，深入探索创新药物与治疗方案，以期为患者带来更多获益，让健康科技，温暖更多生命。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470774519"}